Skip to main content

Ztalmy Disease Interactions

There are 4 disease interactions with Ztalmy (ganaxolone).

Moderate

Antiepileptics (applies to Ztalmy) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals PROD (2002):
  2. "Product Information. Klonopin (clonazepam)." Roche Laboratories PROD (2001):
  3. "Product Information. Dilantin (phenytoin)." Parke-Davis PROD (2001):
  4. "Product Information. Cerebyx (fosphenytoin)." Parke-Davis PROD (2001):
  5. "Product Information. Mysoline (primidone)." Elan Pharmaceuticals PROD (2001):
  6. "Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group (2005):
  7. "Product Information. Sabril (vigabatrin)." Lundbeck Inc (2009):
  8. "Product Information. Potiga (ezogabine)." GlaxoSmithKline (2011):
  9. "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
  10. "Product Information. Briviact (brivaracetam)." UCB Pharma Inc (2016):
  11. "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC (2018):
  12. "Product Information. Xcopri (cenobamate)." SK Life Science, Inc. (2020):
  13. "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
  14. "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc (2022):
  15. "Product Information. Diacomit (stiripentol)." Biocodex USA SUPPL-3 (2022):
  16. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  17. "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals SUPPL-65 (2023):
View all 17 references
Moderate

Ganaxolone (applies to Ztalmy) alcoholism

Moderate Potential Hazard, Moderate plausibility.

Ganaxolone can cause somnolence and sedation; other CNS depressants (including alcohol) could potentiate these effects. Caution is advised when using this agent in patients with alcohol disorders. Patients should be monitored for somnolence and sedation, and patients should be advised not to drive or operate machinery until they know how ganaxolone will affect them.

References

  1. "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc (2022):
Moderate

Ganaxolone (applies to Ztalmy) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effect of liver dysfunction on the pharmacokinetics of ganaxolone has not been studied; since this drug undergoes hepatic clearance, liver dysfunction can increase ganaxolone exposure. Caution is advised in patients with impaired liver function; they should be monitored for side effects and may require a reduced dosage of ganaxolone.

References

  1. "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc (2022):
Minor

Ganaxolone (applies to Ztalmy) renal impairment

Minor Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The effect of renal dysfunction on the pharmacokinetics of ganaxolone has not been studied; however, since renal excretion is a minor elimination pathway, impaired renal function is unlikely to increase ganaxolone exposures significantly. Caution is recommended in these patients.

References

  1. "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc (2022):

Ztalmy drug interactions

There are 401 drug interactions with Ztalmy (ganaxolone).

Ztalmy alcohol/food interactions

There is 1 alcohol/food interaction with Ztalmy (ganaxolone).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer